| A phase II trial was conducted to evaluate any pharmacokinetic drug–drug interactions between cannabidiol and stiripentol or valproate in patients with epilepsy. |
| The combination of cannabidiol and stiripentol led to a small increase in exposure to stiripentol. |
| The combination of cannabidiol and valproate did not cause clinically important changes in the pharmacokinetics of valproate or its metabolite, 2-propyl-4-pentenoic acid (4-ene-VPA). |
| The safety profile of cannabidiol in combination with stiripentol or valproate was consistent with that previously reported. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.